Atyr_Logo.png
European Commission Grants Orphan Drug Designation for aTyr Pharma’s Efzofitimod for Treatment of Sarcoidosis
January 18, 2023 08:00 ET | aTyr Pharma, Inc.
SAN DIEGO, Jan. 18, 2023 (GLOBE NEWSWIRE) --  aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary...
Cingulate_Logo_400x400_twitter.jpg
Cingulate Initiates Phase 3 Study of Lead Asset CTx-1301, Designed as a True Entire Active-Day Treatment for ADHD
January 04, 2023 06:45 ET | Cingulate Inc.
Trial Results Expected 1H 2023 Company to Host Investor and Business Development Meetings Adjacent to Upcoming J.P. Morgan Healthcare Conference in San Francisco KANSAS CITY, Kan., Jan. 04,...
Consolidated Balance Sheet Data
Cingulate Inc. Reports Third Quarter 2022 Financial Results and Provides Clinical and Business Update
November 14, 2022 06:45 ET | Cingulate Inc.
Phase 3 Trial Initiation for Lead ADHD Candidate CTx-1301 in December 2022 Executed Manufacturing Agreement with Societal CDMO 2022 Psych Congress Presentation Demonstrated Ability of Anxiety...
Cingulate_Logo_400x400_twitter.jpg
Cingulate Announces Agreement with Societal CDMO and Provides Clinical Update
October 24, 2022 16:45 ET | Cingulate Inc.
KANSAS CITY, Kan., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Synlogic_Logo_Blue.png
Synlogic Announces Positive Top-Line Phase 2 Data for Phenylketonuria (PKU); SYNB1934 Advances to Phase 3
October 18, 2022 06:59 ET | Synlogic, Inc.
Positive results include clinically meaningful Phe reductions, with a 60% response rate and 42% reduction in plasma Phe among responders across the study population Consistent, positive measures of...
enteralogo.png
Entera Bio Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support an NDA for EB613 for the Treatment of Osteoporosis
October 06, 2022 07:00 ET | Entera Bio Ltd.
JERUSALEM, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, announced...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento Therapeutics Completes Enrollment of Phase 2 Clinical Trial of Resiniferatoxin (RTX) for Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee (OAK) Patients
September 26, 2022 09:00 ET | Sorrento Therapeutics, Inc.
Phase 2 trial of RTX for OAK pain completed enrollment with last patient (n=120) dosedNo limiting toxicities have been encountered during the trial to date. Patients are now being monitored for...
Recardio and FDA Reach Agreement on Pivotal Phase 3 Trial Design
June 01, 2022 09:00 ET | Recardio Inc.
SAN FRANCISCO, June 01, 2022 (GLOBE NEWSWIRE) -- Recardio's Phase 2 trial results demonstrated the excellent safety profile of its lead drug Dutogliptin along with data suggesting potential positive...
Recardio's Positive Phase 2 Results Presented as Latebreaker at World Congress on Acute Heart Failure 2022 in Madrid
May 23, 2022 14:00 ET | Recardio Inc.
SAN FRANCISCO, May 23, 2022 (GLOBE NEWSWIRE) -- Entitled "Phase 2, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of Dutogliptinin Combination with Filgrastim in Early...
GRTS_2021_logoupdate_color.jpg
Gritstone Announces First Patient Enrolled for Phase 2/3 Trial Evaluating Individualized Neoantigen Vaccine GRANITE for First Line (1L) Maintenance Treatment of Metastatic, Microsatellite-Stable Colorectal Cancer (MSS-CRC)
January 13, 2022 07:00 ET | Gritstone bio
-- Phase 2/3 GRANITE-CRC-1L trial has registrational intent -- -- Updated data from Phase 1/2 trial in end-stage metastatic MSS-CRC further support the association of circulating tumor DNA (ctDNA)...